Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2007 Feb 27;96(6):896–902. doi: 10.1038/sj.bjc.6603648

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2007 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

(A–D) Fluoro: n/n: neither Fluoro nor Gem; Fluoro: fluoropyrimidines (fluorouracil, capecitabine, tegafur); Gem: gemcitabine; P: platinum compounds (cisplatin, oxaliplatin, carboplatin). (A) Pooled RRs (RR=CR+PR) and 95% CIs of subgroups of patients, defined by treatment with fluoropyrimidines, gemcitabine, and platinum compounds, regardless of other drugs. The height of the bars correlates with the number of patients. The vertical grey line represents the pooled RR of the Fluoro subgroup (17.1%). The Fluoro-Gem-P subgroup consists of only eight patients and is therefore not shown. Additional P-values: Fluoro vs Gem-P: 0.000; n/n vs all other subgroups: 0.000; n/n-P vs Gem-P: 0.012. (B) Boxplots of RRs of subgroups of trials, defined by treatment with fluoropyrimidines, gemcitabine, and platinum compounds. The height of he boxplots correlates with the number of trials. The vertical grey line represents the median RR of the Fluoro subgroup (19.2%). The Fluoro-Gem-P subgroup consists of only one trial and is therefore not shown. For subgroups consisting of less than five trials, results of single trial are shown and no boxplots are provided. Additional P-values: Fluoro vs Gem-P: 0.000; Fluoro-P vs Gem: 0.033; n/n vs all other subgroups: ⩽0.002; n/n-P vs Gem-P: 0.042. (C) Pooled TCRs (TCR=CR+PR+SD) and 95% CIs of subgroups of patients as in Figure 4A. The vertical grey line represents the pooled TCR of the Fluoro subgroup (50.9%). ^*P-value in comparison to the Fluoro subgroup. Additional P-values: n/n vs all other subgroups: 0.000. (D) Boxplots of TCRs of subgroups of trials as in Figure 4C. The vertical grey line represents the median RR of the Fluoro subgroup (55.0%). Additional P-values: n/n vs all other subgroups: ⩽0.003.